BenQ Medical Technology (4116) reported revenue of NT$444.2 million for Oct 2026, +2.1% year on year and +5.5% from the previous month. Revenue for Jan–Oct 2026 was NT$4.47 billion (+3.6% year on year).
In Oct 2026, it ranked No. 19 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$444.2 million | +2.1% | +5.5% |
| Sep 2026 | NT$421 million | -4.4% | +0.8% |
| Aug 2026 | NT$417.7 million | +0.9% | -3.2% |
| Jul 2026 | NT$431.4 million | -6.6% | -7.3% |
| Jun 2026 | NT$465.5 million | +5.6% | +1.9% |
| May 2026 | NT$456.7 million | +1.2% | -9.9% |
| Apr 2026 | NT$506.9 million | +14.5% | +12.9% |
| Mar 2026 | NT$448.9 million | +5.5% | +17.5% |
| Feb 2026 | NT$381.9 million | -2.3% | -22.7% |
| Jan 2026 | NT$493.8 million | +20.1% | -1.1% |
| Dec 2025 | NT$499.1 million | +14.1% | +13.1% |
| Nov 2025 | NT$441.3 million | -4.4% | +1.5% |
| Oct 2025 | NT$434.8 million | +5.0% | -1.2% |
| Sep 2025 | NT$440.3 million | +3.2% | +6.3% |
| Aug 2025 | NT$414.1 million | +2.6% | -10.4% |
| Jul 2025 | NT$461.9 million | +20.1% | +4.8% |
| Jun 2025 | NT$440.8 million | +9.6% | -2.3% |
| May 2025 | NT$451.3 million | +16.1% | +1.9% |
| Apr 2025 | NT$442.9 million | +15.0% | +4.1% |
| Mar 2025 | NT$425.6 million | +16.1% | +8.9% |
| Feb 2025 | NT$391 million | +21.5% | -4.9% |
| Jan 2025 | NT$411.3 million | +11.6% | -5.9% |
| Dec 2024 | NT$437.3 million | +5.2% | -5.3% |
| Nov 2024 | NT$461.6 million | +15.8% | +11.5% |
| Oct 2024 | NT$414 million | +5.0% | -3.0% |
Jan–Oct 2026 cumulative: NT$4.47 billion (+3.6% YoY)
Other Biotech & Medical companies
Compare with peers: BenQ Medical Technology vs PEC / BenQ Medical Technology vs Lotus Pharm / BenQ Medical Technology vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16